Clinical trials: Blepharospasm, Benign Essential

Benign Essential Blepharospasm

rTMS and Botulinum Toxin in Benign Essential Blepharospasm

• Completed
• Age: 30 to 75 years
• Medical device
• Results posted

Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients.

Trial name

NCT02370875

Testing

Magstim RapidStim2

Where

United States

Volunteers

12 people

Sponsor

University of Florida